Sept 14 - Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to ...

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Danish drugmaker Novo Nordisk (NVO) and Orbis Medicines struck an up to $1.4 billion licensing deal for the private company ...

Novo Nordisk (NVO) stock rose 4% after announcing an Anthropic AI deal and receiving a European approval recommendation for ...

The Wegovy maker is betting that a shorter name will help it resonate more with consumers as it competes with rival Eli Lilly ...

Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall ...

Novo Nordisk stock gains as Sogroya wins a key EU recommendation for children with idiopathic short stature, bringing broader EU approval a step closer.

Novo Nordisk has launched a global rebrand that will see the healthcare company increasingly use Novo as its day-to-day name ...

The fresh trigger for Novo Nordisk (CPSE:NOVO B) is a CHMP green light for FREHEMGO, a haemophilia A therapy that could add a rare-disease revenue stream alongside its core obesity and diabetes ...

Novo Nordisk (NVO) stock jumped 4% after unveiling an AI collaboration with Anthropic and securing European approval ...

Novo Nordisk A/S ( NVO) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for ...

Novo Nordisk announced Monday that it is rebranding itself as "Novo" along with updating its corporate culture as it competes ...